• Regulatory NewsRegulatory News

    FDA Works to Reduce Dog Testing in Drug Development

    US Food and Drug Administration (FDA) researchers are working to develop a new informatics model to reduce the reliance on dogs to conduct studies in animal drug development.   The agency’s new study, which was proposed on Friday, is intended to aid animal drug developers in conducting certain research without the need for product testing on dogs.   Animal drug developers would be able to use the new model as a mechanism for comparing blood levels of certain oral...
  • Regulatory NewsRegulatory News

    FDA Finalizes Testicular Toxicity Guidance

    The US Food and Drug Administration (FDA) on Wednesday finalized guidance for drugmakers on identifying and evaluating early signals that could indicate whether a drug might have adverse effects on the testes and when clinical trials are necessary to assess those risks.   Specifically, the 14-page guidance lays out recommendations for identifying nonclinical signals that suggest risk of testicular toxicity; conducting nonclinical assessments to further evaluate the ris...
  • RAPS' LatestRAPS' Latest

    Looking Back at the 2018 Regulatory Convergence: the Newsworthy and Noteworthy

    Attendees of RAPS’ 2018 Regulatory Convergence in Vancouver, 1–4 October, were among the first to learn about important developments and the latest news on topics including the coming EU Medical Device Regulation (MDR), the US Food and Drug Administration’s (FDA) cybersecurity policies and the results of RAPS’ comprehensive global salary survey of regulatory professionals. The event also marked the first time RAPS’ annual gathering has been held in Canada. The confer...
  • Regulatory NewsRegulatory News

    CDRH Drafts New Framework to Create a Pediatric Device Safety Network

    A draft framework is in the works at the US Food and Drug Administration (FDA) to create an innovative safety net for pediatric medical devices, Vasum Peiris, Chief Medical Officer for pediatrics and special populations at the Center for Devices and Radiological Health (CDRH), told Focus . The new framework is “centered around the fundamental issue of safety for children,” Peiris said, posing the question “where can we actually innovate safely?” Pediatric academic medic...
  • Regulatory NewsRegulatory News

    Cybersecurity: CDRH to Update 2014 Premarket Policies

    Ahead of a new US Food and Drug Administration (FDA) draft guidance set to be released in FY 2019, lead of cybersecurity initiatives at the Center for Devices and Radiological Health (CDRH) Suzanne Schwartz previewed policy changes at RAPS’ 2018 Convergence.   The US healthcare industry has become a target for cyberattacks over the past few years and this has been partly linked to inadequate device designs, which must undergo regulatory premarket reviews to mitigate cy...
  • Regulatory NewsRegulatory News

    CDRH Looks to Expand Case for Quality Program

    With plans to establish a full program next year, the Center for Devices and Radiological Health (CDRH) at the US Food and Drug Administration (FDA) recently met its goal to complete at least 30 appraisals under the voluntary case for quality (CfQ) pilot program by year’s end. CDRH had already completed a total of 35 appraisals across 18 device companies, as of earlier this month, in collaboration with the Medical Device Innovation Consortium (MDIC) and the CMMI Institut...
  • Regulatory NewsRegulatory News

    CDRH Works to Develop Proposed De Novo Regulation

    The regulatory review pathway for novel devices will receive major policy clarifications by mid-2019, program lead at the US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) said during a forum at RAPS’ 2018 Regulatory Convergence. The de novo program—established about 20 years ago as a mechanism to evaluate devices that are by statute automatically classified into Class III—saw an anomaly in 2017 prior to its first user fees, noted...
  • Regulatory NewsRegulatory News

    KPMG/RAPS Survey Digs in to Device Makers' EU MDR Preparedness

    A new report from KPMG and RAPS sheds light on how prepared medical device companies are for the new European medical device regulation (MDR) as the 2020 compliance deadline approaches.   The report, which is based on a survey conducted in June 2018, received responses from more than 200 regulatory and quality professionals at medical device companies worldwide. It was released during RAPS' 2018 Convergence in Vancouver, Canada.    One of the key findings relates t...
  • Regulatory NewsRegulatory News

    Brazil’s ANVISA to Eliminate Backlog of Applications

    Brazilian drug regulator ANVISA said Wednesday at RAPS’ Regulatory Convergence that it would eliminate a backlog of new and generic drug applications by January 2019. The elimination of the backlog will free the regulator up for new projects, and comes as more than 800 applications were backlogged as of January 2017, Raphael Sanches Pereira, general manager at ANVISA said. Pereira also said that ANVISA by the end of this year will make a proposal to rely on Certif...
  • Regulatory NewsRegulatory News

    Reorganization of OND to Support New Drug Review Modernization, Woodcock Says

    The reorganization of the US Food and Drug Administration’s (FDA) Office of New Drugs will help support the modernization of new drug reviews, Janet Woodcock, head of FDA’s Center for Drug Evaluation and Research told attendees of RAPS’ Regulatory Convergence on Thursday. She said the plan is to begin restructuring the premarket safety review process and then move into the investigational new drug (IND) application process. By frontloading a lot of the activities, th...
  • Regulatory NewsRegulatory News

    Survey: Expected Shortage of Notified Bodies Under EU MDR/IVDR

    Findings from a recent survey of notified bodies (NB) in Europe suggests the audits needed for compliance with the new medical device regulation (MDR) will not be completed in time, TÜV SÜD Product Service GmbH VP Bassil Akra said Wednesday at 2018 Regulatory Convergence.   The survey conducted by Team-NB was designed to assess the impact of a contentious issue with regard to the ongoing transition to the new EU MDR and in vitro diagnostic regulation (IVDR). This r...
  • RAPS' LatestRAPS' Latest

    RAPS Releases Results of Compensation Survey of Regulatory Professionals

    RAPS today released the results of its comprehensive global survey of healthcare product regulatory professionals, offering a detailed look at how much they earn, which products they work on, what their work entails, and how their roles within their organizations have evolved. RAPS’ 2018 Global Compensation & Scope of Practice Report for the Regulatory Profession aggregates salary data for more than 2,300 respondents from 64 countries and breaks down median and averag...